Holen Sie sich die Stockscreener-App
7.66
1.16%
-0.09
Handel nachbörslich:
7.65
-0.010
-0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.75
Offen:
$7.72
24-Stunden-Volumen:
943.61K
Relative Volume:
0.71
Marktkapitalisierung:
$1.06B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-14.45
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
-0.91%
1M Leistung:
-9.24%
6M Leistung:
+6.83%
1J Leistung:
+53.51%
1-Tages-Spanne:
$7.65
$7.845
1-Wochen-Bereich:
$7.59
$7.845
52-Wochen-Spanne:
$4.77
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
7.66 | 1.06B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Aurinia Sues Galenicum to Block Copies of Lupkynis Kidney Drug - Bloomberg Law News
Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement - Law360
High Growth Tech Stocks To Watch In The US Market - simplywall.st
Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)? - Yahoo
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
(AUPH) Trading Signals - news.stocktradersdaily.com
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Aurinia Pharmaceuticals Announces Financial Growth and Pipeline Progress in 2024 - Zenopa
Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome - marketscreener.com
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 - Investing.com India
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 By Investing.com - Investing.com UK
Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options - Nasdaq
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point - Yahoo Finance
Aurinia Pharmaceuticals stock climbs on insider buying - MSN
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 - Investing.com Australia
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals CEO Peter Greenleaf sells shares worth $2.87 million - Investing.com India
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 By Investing.com - Investing.com South Africa
Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks
Aurinia Pharmaceuticals’ chief medical officer sells $97,912 in stock - Investing.com
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 - Investing.com India
Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - Nasdaq
Objective long/short (AUPH) Report - Stock Traders Daily
LAWSUITS FILED AGAINST ABBV, SDIG and AUPHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Atria Wealth Solutions Inc. Buys Shares of 15,000 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo
IFP Advisors Inc Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks
Aurinia Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
Aurinia Pharmaceuticals Reports Balanced Earnings with Growth and Challenges - TipRanks
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga
Aurinia: Q4 Earnings Snapshot - CT Insider
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates - MSN
Earnings call transcript: Aurinia Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com
Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aurinia Pharmaceuticals Swings to Q4 Earnings, Revenue Rises -February 27, 2025 at 09:26 am EST - Marketscreener.com
Aurinia Pharmaceuticals Reports Strong Financial Growth in 2024 - TipRanks
Aurinia Pharmaceuticals Files Form 8-K Indicating Key Corporate Event - TipRanks
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):